Literature DB >> 26324860

Patient-reported outcomes in core domain sets for rheumatic diseases.

Lilian H D van Tuyl1, Maarten Boers1,2.   

Abstract

Patient-reported outcomes (PROs) are abundant in rheumatology and their numbers continue to increase. But which of the available measures are most important? Core outcome sets-including groups of domains and instruments for measuring them-have been defined for many rheumatic diseases, with the aim that all these outcomes should be measured in every clinical trial. The subgroup of PROs included in these core sets is, therefore, undoubtedly important. This Review summarizes the PROs included in core outcome sets developed for use in clinical trials across a wide range of rheumatic diseases. Three PROs are commonly utilized across the majority of rheumatic conditions: pain, physical functioning and the patient global assessment of disease activity. However, additional research is needed to fully understand the role of the patient global assessment of disease activity, to distinguish specific domains within the broad concept of health-related quality of life, and to work towards consensus on the choice between generic and disease-specific instruments in various contexts.

Entities:  

Mesh:

Year:  2015        PMID: 26324860     DOI: 10.1038/nrrheum.2015.116

Source DB:  PubMed          Journal:  Nat Rev Rheumatol        ISSN: 1759-4790            Impact factor:   20.543


  81 in total

Review 1.  Top 10 recent developments in health-related quality of life in patients with systemic lupus erythematosus.

Authors:  Anisha B Dua; Zahi Touma; Sergio Toloza; Meenakshi Jolly
Journal:  Curr Rheumatol Rep       Date:  2013-12       Impact factor: 4.592

2.  Gout Assessment Questionnaire: Initial results of reliability, validity and responsiveness.

Authors:  H H Colwell; B J Hunt; D J Pasta; W A Palo; S D Mathias; N Joseph-Ridge
Journal:  Int J Clin Pract       Date:  2006-08-15       Impact factor: 2.503

3.  Preliminary definition of improvement in juvenile arthritis.

Authors:  E H Giannini; N Ruperto; A Ravelli; D J Lovell; D T Felson; A Martini
Journal:  Arthritis Rheum       Date:  1997-07

Review 4.  Quality-of-life measurements versus disease activity in systemic lupus erythematosus.

Authors:  Adnan N Kiani; Michelle Petri
Journal:  Curr Rheumatol Rep       Date:  2010-08       Impact factor: 4.592

Review 5.  Proposed preliminary core set measures for disease outcome assessment in adult and juvenile idiopathic inflammatory myopathies.

Authors:  F W Miller; L G Rider; Y L Chung; R Cooper; K Danko; V Farewell; I Lundberg; C Morrison; L Oakley; I Oakley; C Pilkington; J Vencovsky; K Vincent; D L Scott; D A Isenberg
Journal:  Rheumatology (Oxford)       Date:  2001-11       Impact factor: 7.580

Review 6.  Establishing a core domain set to measure rheumatoid arthritis flares: report of the OMERACT 11 RA flare Workshop.

Authors:  Vivian P Bykerk; Elisabeth Lie; Susan J Bartlett; Rieke Alten; Annelies Boonen; Robin Christensen; Daniel E Furst; Sarah Hewlett; Amye L Leong; Anne Lyddiatt; Lyn March; James E May; Pam Montie; Ana-Maria Orbai; Christoph Pohl; Marieke Scholte Voshaar; Thasia Woodworth; Clifton O Bingham; Ernest H Choy
Journal:  J Rheumatol       Date:  2014-03-01       Impact factor: 4.666

7.  Randomized clinical trials and longitudinal observational studies in systemic lupus erythematosus: consensus on a preliminary core set of outcome domains.

Authors:  J S Smolen; V Strand; M Cardiel; S Edworthy; D Furst; D Gladman; C Gordon; D A Isenberg; J H Klippel; M Petri; L Simon; P Tugwell; F Wolfe
Journal:  J Rheumatol       Date:  1999-02       Impact factor: 4.666

8.  Reporting disease activity in clinical trials of patients with rheumatoid arthritis: EULAR/ACR collaborative recommendations.

Authors:  D Aletaha; R Landewe; T Karonitsch; J Bathon; M Boers; C Bombardier; S Bombardieri; H Choi; B Combe; M Dougados; P Emery; J Gomez-Reino; E Keystone; G Koch; T K Kvien; E Martin-Mola; M Matucci-Cerinic; K Michaud; J O'Dell; H Paulus; T Pincus; P Richards; L Simon; J Siegel; J S Smolen; T Sokka; V Strand; P Tugwell; D van der Heijde; P van Riel; S Vlad; R van Vollenhoven; M Ward; M Weinblatt; G Wells; B White; F Wolfe; B Zhang; A Zink; D Felson
Journal:  Ann Rheum Dis       Date:  2008-10       Impact factor: 19.103

Review 9.  Polymyalgia Rheumatica (PMR) Special Interest Group at OMERACT 11: outcomes of importance for patients with PMR.

Authors:  Sarah L Mackie; Seher Arat; Jose da Silva; Catia Duarte; Sue Halliday; Rod Hughes; Marianne Morris; Colin T Pease; Jeffrey W Sherman; Lee S Simon; Maggie Walsh; René Westhovens; Samy Zakout; John R Kirwan
Journal:  J Rheumatol       Date:  2014-02-01       Impact factor: 4.666

Review 10.  Outcome measures in rheumatoid arthritis randomised trials over the last 50 years.

Authors:  Jamie J Kirkham; Maarten Boers; Peter Tugwell; Mike Clarke; Paula R Williamson
Journal:  Trials       Date:  2013-10-09       Impact factor: 2.279

View more
  17 in total

Review 1.  Update on outcome assessment in myositis.

Authors:  Lisa G Rider; Rohit Aggarwal; Pedro M Machado; Jean-Yves Hogrel; Ann M Reed; Lisa Christopher-Stine; Nicolino Ruperto
Journal:  Nat Rev Rheumatol       Date:  2018-04-12       Impact factor: 20.543

2.  Responsiveness and Minimally Important Differences for 4 Patient-Reported Outcomes Measurement Information System Short Forms: Physical Function, Pain Interference, Depression, and Anxiety in Knee Osteoarthritis.

Authors:  Augustine C Lee; Jeffrey B Driban; Lori Lyn Price; William F Harvey; Angie Mae Rodday; Chenchen Wang
Journal:  J Pain       Date:  2017-05-10       Impact factor: 5.820

3.  Validity and reliability of the Short Form 36 Health Surveys (SF-36) among patients with spondyloarthritis in Singapore.

Authors:  Yu Heng Kwan; Warren Weng Seng Fong; Nai Lee Lui; Si Ting Yong; Yin Bun Cheung; Rahul Malhotra; Truls Østbye; Julian Thumboo
Journal:  Rheumatol Int       Date:  2016-09-23       Impact factor: 2.631

4.  Evaluation of the performance of extreme patient-reported outcomes as surrogate markers for fibromyalgia in axial spondyloarthritis.

Authors:  Daniela Santos-Faria; Maxime Dougados; Laure Gossec; Serge Perrot; Anna Moltó
Journal:  Rheumatol Int       Date:  2018-11-09       Impact factor: 2.631

5.  Factors associated with anxiety and depression in rheumatoid arthritis patients: a cross-sectional study.

Authors:  Miyabi Uda; Motomu Hashimoto; Ryuji Uozumi; Mie Torii; Takao Fujii; Masao Tanaka; Moritoshi Furu; Hiromu Ito; Chikashi Terao; Wataru Yamamoto; Genichi Sugihara; Yukako Nakagami; Tsuneyo Mimori; Kazuko Nin
Journal:  Adv Rheumatol       Date:  2021-10-29

6.  Is the Rheumatoid Arthritis Impact of Disease (RAID) score a meaningful instrument for other inflammatory rheumatic diseases? A cross-sectional analysis of data from the German National Database.

Authors:  Katja Thiele; Katinka Albrecht; Angela Zink; Martin Aringer; Kirsten Karberg; Susanna Späthling-Mestekemper; Ulrich von Hinüber; Johanna Callhoff
Journal:  RMD Open       Date:  2022-07

Review 7.  Patient-reported outcomes in trials of patients with polymyalgia rheumatica: a systematic literature review.

Authors:  Annie Huang; Isabel Castrejon
Journal:  Rheumatol Int       Date:  2016-01-14       Impact factor: 2.631

8.  Discordance of global assessment by patients and physicians is higher in osteoarthritis than in rheumatoid arthritis: a cross-sectional study from routine care.

Authors:  Isabel Castrejon; Najia Shakoor; Jacquelin R Chua; Joel A Block
Journal:  Rheumatol Int       Date:  2018-10-06       Impact factor: 2.631

9.  Measuring everyday functional competence using the Rasch assessment of everyday activity limitations (REAL) item bank.

Authors:  Martijn A H Oude Voshaar; Peter M Ten Klooster; Harald E Vonkeman; Mart A F J van de Laar
Journal:  Qual Life Res       Date:  2017-06-21       Impact factor: 4.147

10.  Electronic patient-reported outcome measures using mobile health technology in rheumatology: A scoping review.

Authors:  Jaclyn Shelton; Sierra Casey; Nathan Puhl; Jeanette Buckingham; Elaine Yacyshyn
Journal:  PLoS One       Date:  2021-07-22       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.